Breaking News

Nexcella Completes 3rd NXC-201 Batch at U.S. CAR-T Site

Successful completion supports expansion of its ongoing clinical trial in relapsed/refractory AL Amyloidosis.

Nexcella, Inc., clinical-stage biopharmaceutical company, reported the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 at its U.S. manufacturing site. NXC-201 will be manufactured for each individual patient using the patient’s own T cells at its state-of-the-art cellular immunotherapy manufacturing facility in California. “We believe the completion of our 3rd U.S. engineering batch represents an important thresho...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters